CRISPR targeting of mmu-miR-21a through a single adeno-associated virus vector prolongs survival of glioblastoma-bearing mice

Mol Ther. 2025 Jan 8;33(1):133-151. doi: 10.1016/j.ymthe.2024.11.023. Epub 2024 Nov 19.

Abstract

Glioblastoma (GB), the most aggressive tumor of the central nervous system (CNS), has poor patient outcomes with limited effective treatments available. MicroRNA-21 (miR-21(a)) is a known oncogene, abundantly expressed in many cancer types. miR-21(a) promotes GB progression, and lack of miR-21(a) reduces the tumorigenic potential. Here, we propose a single adeno-associated virus (AAV) vector strategy targeting mmu-miR-21a using the Staphylococcus aureus Cas9 ortholog (SaCas9) guided by a single-guide RNA (sgRNA). Our results demonstrate that AAV8 is a well-suited AAV serotype to express SaCas9-KKH/sgRNA at the tumor site in an orthotopic GB model. The SaCas9-KKH induced a genomic deletion, resulting in lowered mmu-miR-21a levels in the brain, leading to reduced tumor growth and improved overall survival. In this study, we demonstrated that disruption of genomic mmu-miR-21a with a single AAV vector influenced glioma development, resulting in beneficial anti-tumor outcomes in GB-bearing mice.

Keywords: CRISPR-Cas; adeno-associated virus; gene editing; glioblastoma; mmu-miR-21a.

MeSH terms

  • Animals
  • Brain Neoplasms / genetics
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy
  • CRISPR-Cas Systems*
  • Cell Line, Tumor
  • Dependovirus* / genetics
  • Disease Models, Animal
  • Gene Editing / methods
  • Gene Targeting
  • Genetic Therapy / methods
  • Genetic Vectors* / administration & dosage
  • Genetic Vectors* / genetics
  • Glioblastoma* / genetics
  • Glioblastoma* / pathology
  • Glioblastoma* / therapy
  • Humans
  • Mice
  • MicroRNAs* / genetics
  • RNA, Guide, CRISPR-Cas Systems / genetics
  • Xenograft Model Antitumor Assays

Substances

  • MicroRNAs
  • RNA, Guide, CRISPR-Cas Systems
  • MIRN21 microRNA, mouse